Needham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $50 Price Target

Needham analyst Ami Fadia has reiterated a Buy rating on Harmony Biosciences Holdings (NASDAQ: HRMY) and maintained a price target of $50 for the stock.